Phase II study of linvoseltamab in patients with asymptomatic multiple myeloma at high risk of progression to multiple myeloma.

CLINICAL TRIAL WITH MEDICINES

Home · TEC24-Hematology and Gene Therapy Research Group: HemaTerGe

Clinical trial information

Promoter: ICON CLINICAL RESEARCH LTD
Phase: II
Execution start: 29/01/2024
End of execution: 29/08/2032
IP: MARIA ESTHER CLAVERO SANCHEZ